Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Amortizatization of Intangibles (2021 - 2025)

SAB Biotherapeutics' Amortizatization of Intangibles history spans 5 years, with the latest figure at $36864.0 for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 68.91% year-over-year to $36864.0; the TTM value through Dec 2025 reached $102570.0, up 16.79%, while the annual FY2025 figure was $88631.0, 2.08% up from the prior year.
  • Amortizatization of Intangibles reached $36864.0 in Q4 2025 per SABSW's latest filing, up from $22000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $41259.0 in Q1 2021 to a low of $21706.0 in Q1 2025.
  • Average Amortizatization of Intangibles over 5 years is $28472.6, with a median of $23858.0 recorded in 2022.
  • Peak YoY movement for Amortizatization of Intangibles: plummeted 40.09% in 2022, then soared 68.91% in 2025.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $41206.0 in 2021, then tumbled by 40.02% to $24716.0 in 2022, then fell by 11.35% to $21910.0 in 2023, then dropped by 0.39% to $21824.0 in 2024, then skyrocketed by 68.91% to $36864.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Amortizatization of Intangibles are $36864.0 (Q4 2025), $22000.0 (Q3 2025), and $22000.0 (Q2 2025).